Myofibroblastic Dermatofibroma: An Unusual Variant / Miofibroblastni Dermatofibrom: Neuobičajena Varijacija : Serbian Journal of Dermatology and Venerology

www.degruyter.com uses cookies, tags, and tracking settings to store information that help give you the very best browsing experience.
To understand more about cookies, tags, and tracking, see our Privacy Statement
I accept all cookies for the De Gruyter Online site

Jump to ContentJump to Main Navigation

Serbian Journal of Dermatology and Venereology

The Journal of Serbian Association of Dermatovenereologists (SAD)

Open Access
VolumeIssuePage

Myofibroblastic Dermatofibroma: An Unusual Variant / Miofibroblastni Dermatofibrom: Neuobičajena Varijacija

Cynthia Okoduwa1 / Robyn D. Siperstein1 / Wen Chen1 / Rajit Malliah1 / Valerie Fitzhugh1 / W. Clark Lambert1 / 1

1Dermatology and Pathology, New Jersey Medical School, 185 South Orange Avenue, Newark, New Jersey 07103

This content is open access.

Citation Information: Serbian Journal of Dermatology and Venerology. Volume 1, Issue 1, Pages 34–37, ISSN (Print) 1821-0902, DOI: 10.2478/v10249-011-0099-4, February 2013

Publication History

Published Online:
2013-02-12

Abstract

Myofibroblastic dermatofibroma (MFD) is an unusual neoplasm characterized by a predominance of myofibroblastic differentiation. It is extremely rare and it is not well described. Expressions of smooth muscle actin, CD34, S-100, desmin, CD31, and Factor XIIIa were evaluated along with hematoxylin-eosin and trichrome staining of fixed tissue specimens from a fibrohistiocytic neoplasm. The neoplasm demonstrated a storiform pattern characteristic of fibrohistiocytic origin. It was strongly and diffusely positive for smooth muscle actin and vimentin, and negative for all other stains performed. A trichrome stain showed the entire tumor to be blue, demonstrating the collagenous and fibrous tissue to a marked degree. MFD is a distinct variant of dermatofibroma characterized by a predominance of myofibroblastic differentiation.

Sažetak

Uvod: Miofbroblastni dermatofbrom (MFD) neobičan je tumor karakterističan po tome što kod njega preovladava miofbroblastna diferencijacija. Veoma je redak i nedovoljno opisan u literaturi.

Metode: Ispitivanje je obuhvatilo ekspresiju aktina glatkih mišića, CD34, S-100, dezmin, CD31 i faktor XIIIa, kao i histopatološke analize hematoksilin-eozin i trihromnim bojenjem fksiranih uzoraka tkiva fbro-histiocitnih tumora.

Rezultati: Histopatološki, tumor se sastojao od vretenastih ćelija, karakterističnih za fbrohistiocitno poreklo. Imunohemijskom analizom dobijena je pozi-tivna reakcija na aktin i vimentin glatkih mišića, dok je na ostala bojenja reakcija bila negativna. Trihrom-nim bojenjem dobijena je potpuna obojenost tumora plavom bojom, što je do određene granice demonstri-ralo i kolagenozno i fbrozno tkivo.

Zaključak: MFD je posebna varijanta dermatofbroma sa karakterističnim prisustvom miofbroblastne diferen-cijacije.

  • 1. Zelger BG, Zelger BWH. Myofibroblastic dermatofibroma: a cutaneous variant of intranodal myofibroblastoma. Am J Dermatopathol 1996;18:441.

  • 2. Zelger B, Zelger G, Burgdorf WHC. Dermatofibroma: a critical evaluation. Int J Surg Pathol 2004;12:333-44. [PubMed] [CrossRef]

  • 3. Eyden B. Fibroblast phenotype plasticity: relevance for understanding heterogenity in „fibroblastic“ tumors. Ultrastruct Pathol 2004;28:307-19. [CrossRef]

  • 4. Fisher C. Myofibroblastic malignancies. Adv Anat Pathol 2004;11:190-201. [PubMed] [CrossRef]

  • 5. Zelger BG, Sidoroff A, Zelger B. Combined dermatofibroma: co-existence of two or more variant patterns in a single lesion. Histopathology 2000;36:529-39. [CrossRef]

  • 6. Eyden B. The myofibroblast: a study of normal, reactive and neoplastic tissues, with an emphasis on ultrastructure. part 2 - tumours and tumour-like lesions. J Submicrosc Cytol Pathol 2005;37:231-96.

  • 7. Fletcher CD. Myofibroblastic tumours: an update. Verh Deutsc Ges Pathol 1998;82:75-82.

  • 8. Calonje E. Is cutaneous benign fibrous histiocytoma (dermatofibroma) a reactive inflammatory process or neoplasm? Histopathology 2000;37:278-80. [CrossRef] [PubMed]

  • 9. Eyden B. Electron microscopy in the study of myofibroblastic lesions. Semin Diagn Pathol 2003;20:13-24.

  • 10. Zelger BG, Zelger B. Dermatofibroma (fibrous histiocytoma): An inflammatory or neoplastic disorder? Histopathology 2001;38:379-81. [PubMed] [CrossRef]

  • 11. Zelger BW, Zelger BG, Rappersberger K. Prominent myofibroblastic differentiation: a pitfall in the diagnosis of dermatofibroma. Am J Dermatopathol 1997;19:138-46.

  • 12. Eyden BP, Harris M, Greywoode GJ, Christensen L, Banerjee SS. Intranodal myofibroblastoma: report of a case. Ultrastrucl Pathol 1996;20:79-88. [CrossRef]

  • 13. Eyden BP, Ponting J, Defining the myofibroblast: normal tissues, with special reference to the stromal cells of Wharton’s jelly in human umbilical cord. J Submicrosc Cytol Pathol 1994;26:347-55.

  • 14. Dishop MK, Warner BW, Dehner LP, et al. Successful treatment of inflammatory myofibroblastic tumor with malignanttransformation by surgical resection and chemotherapy. J Pediatr Hematol Oncol 2003;25:153-8. [CrossRef]

Comments (0)

Please log in or register to comment.